Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KMHHU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
TRS-005
|
|||||
| Synonyms |
TRS-005; TRS005
Click to Show/Hide
|
|||||
| Organization |
Zhejiang Teruisi Pharmaceutical Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
4.2
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
B-lymphocyte antigen CD20 (MS4A1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
42.20% (all)
52.90% (DLBCL) 26.30% (FL) 60.00% (MCL) 66.70% (MZL) 0.00% (SLL/CLL) 42.90% (0.50 mg/kg) 33.30% (1.00 mg/kg) 43.80% (1.50 mg/kg) 50.00% (1.80 mg/kg) |
|||
| Patients Enrolled |
CD20-positive B-cell non Hodgkin lymphoma (NHL) and had failed 2 prior lines of standard treatment.
|
||||
| Administration Dosage |
Seven dose cohorts (0.10, 0.50, 1.00, 1.50, 1.80, 2.10, 2.30 mg/kg iv d1,q21d).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05395533 | Clinical Status | Phase 1 | ||
| Clinical Description | A multicenter, single-arm, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics and effectiveness of TRS005 in patients with relapsed or refractory CD20-positive B-NHL. | ||||
References